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in a European Cohort
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IMPORTANCE The 2013 American College of Cardiology/American Heart Association
(ACC/AHA) guidelines introduced a predictionmodel and lowered the threshold for
treatment with statins to a 7.5% 10-year hard atherosclerotic cardiovascular disease (ASCVD)
risk. Implications of the new guideline’s threshold andmodel have not been addressed in
non-US populations or compared with previous guidelines.
OBJECTIVE To determine population-wide implications of the ACC/AHA, the Adult Treatment
Panel III (ATP-III), and the European Society of Cardiology (ESC) guidelines using a cohort of
Dutch individuals aged 55 years or older.
DESIGN, SETTING, AND PARTICIPANTS We included 4854 Rotterdam Study participants
recruited in 1997-2001. We calculated 10-year risks for “hard” ASCVD events (including fatal
and nonfatal coronary heart disease [CHD] and stroke) (ACC/AHA), hard CHD events (fatal
and nonfatal myocardial infarction, CHDmortality) (ATP-III), and atherosclerotic CVD
mortality (ESC).
MAIN OUTCOMES ANDMEASURES Events were assessed until January 1, 2012. Per guideline,
we calculated proportions of individuals for whom statins would be recommended and
determined calibration and discrimination of risk models.
RESULTS Themean agewas 65.5 (SD, 5.2) years. Statinswould be recommended for 96.4%
(95%CI, 95.4%-97.1%; n = 1825) ofmen and65.8% (95%CI, 63.8%-67.7%; n = 1523) ofwomen
by theACC/AHA, 52.0% (95%CI, 49.8%-54.3%; n = 985) ofmen and 35.5% (95%CI,
33.5%-37.5%; n = 821) ofwomenby theATP-III, and66.1% (95%CI, 64.0%-68.3%; n = 1253) of
men and 39.1% (95%CI, 37.1%-41.2%; n = 906) ofwomenby ESC guidelines.With theACC/AHA
model, average predicted risk vs observed cumulative incidence of hard ASCVDeventswas
21.5% (95%CI, 20.9%-22.1%) vs 12.7% (95%CI, 11.1%-14.5%) formen (192 events) and 11.6%
(95%CI, 11.2%-12.0%) vs 7.9% (95%CI, 6.7%-9.2%) forwomen (151 events). Similar
overestimation occurredwith theATP-IIImodel (98 events inmen and62 events inwomen) and
ESCmodel (50 events inmen and 37 events inwomen). The C statisticwas0.67 (95%CI,
0.63-0.71) inmen and0.68 (95%CI, 0.64-0.73) inwomen for hard ASCVD (ACC/AHA), 0.67
(95%CI, 0.62-0.72) inmen and0.69 (95%CI, 0.63-0.75) inwomen for hard CHD (ATP-III), and
0.76 (95%CI, 0.70-0.82) inmen and0.77 (95%CI, 0.71-0.83) inwomen for CVDmortality (ESC).
CONCLUSIONS AND RELEVANCE In this European population aged 55 years or older, proportions
of individuals eligible for statins differed substantially among the guidelines. TheACC/AHA
guidelinewould recommend statins for nearly all men and two-thirds ofwomen, proportions
exceeding thosewith theATP-III or ESC guidelines. All 3 riskmodels provided poor calibration
andmoderate to good discrimination. Improving risk predictions and setting appropriate
population-wide thresholds are necessary to facilitate better clinical decisionmaking.
JAMA. 2014;311(14):1416-1423. doi:10.1001/jama.2014.2632
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P revention of cardiovascular disease (CVD), the leadingcause of deathworldwide,1,2 remains feasible3 yet sub-optimal. The common approach in CVD primary pre-
vention is to identify individuals at high enough risk for car-
diovascular events to justify targeting themformore intensive
lifestyle interventions,pharmacological interventions,orboth.
The CVD prevention guidelines developed by the Na-
tional Cholesterol Education Program expert panel,4 suc-
ceededby theAmericanCollegeofCardiology/AmericanHeart
Association (ACC/AHA) task force5, and the European Society
ofCardiology (ESC)6 are themajor guidelines influencingclini-
cal practice. While the Adult Treatment Panel III (ATP-III)
guidelineswerebasedon the 10-year riskof coronaryheartdis-
ease (CHD) only,4 the ACC/AHA guidelines broaden to com-
prise risk of all hard atherosclerotic CVD (ASCVD), including
CHD and stroke,5 using the Pooled Cohort equations.7 An ad-
ditional substantial change in the US guideline is a lower risk
threshold for statin treatment in asymptomatic individuals
from 20% CHD risk in the ATP-III guidelines4 to 7.5% ASCVD
risk in the new guidelines.5 The potential implications of the
ACC/AHA guidelines in largely widening the populations en-
dorsed for treatmentand theaccuracyof theACC/AHArisk cal-
culator have received much attention.8-12
Tobe clinically useful, risk predictionmodels shouldpro-
vide good discrimination. Because decisions for statin treat-
ment are based on an individual’s absolute risk, calibration of
the riskpredictionmodelsaswell as the risk threshold for treat-
ment are important. Varying approaches to CVD risk estima-
tion and application of different criteria for therapeutic rec-
ommendationswould translate into substantial differences in
proportions of individuals qualifying for treatment at a popu-
lation level.We therefore aimed to determine implications of
the ACC/AHA, the ATP-III, and the ESC guidelines in a pro-
spectivecohortofDutch individuals aged55yearsorolder.Our
first aimwas to determinewhat proportion of the population
would be treated based on each guideline.We then sought to
examine discrimination and calibration of the 3 risk predic-
tion models underlying these guidelines.
Methods
Study Population
Analyses were performed within the framework of the Rot-
terdam Study, a prospective population-based cohort study
among persons aged 55 years or older in the Ommoord dis-
trict of Rotterdam, theNetherlands. The rationale and design
of theRotterdamStudyhavebeendescribed elsewhere.13 The
baseline examination took place in 1990-1993 (RS-I). In 2000,
the cohort was extended to include inhabitants who reached
the age of 55 years in 1990-2000 and persons aged 55 years or
olderwhomigrated into the research area (RS-II). The Rotter-
damStudywas approved by theMedical Ethics Committee of
theErasmusMedicalCenter andall participantsprovidedwrit-
ten informed consent.
The present study used data from the third examination
of the original cohort (RS-I, recruited 1997-1999) and the first
examination of the extended cohort (RS-II, recruited 2000-
2001). Among theparticipants aged 75 years or younger, there
were 2209 men and 2645 women with measurements re-
quired for theanalyses.Among these individuals, 315menand
330 women were receiving statin treatment at baseline and
thereforewereexcluded fromthepopulation forwhomtheeli-
gibility for treatment based on each guideline was assessed.
For furtheranalysesonexamining theperformanceofeachrisk
scoring model, exclusions were made using the criteria from
each guideline.
Main OutcomeMeasures and Follow-up
MainoutcomeswerehardASCVD, composedof fatal andnon-
fatal myocardial infarction (MI), other CHD mortality, and
stroke; hardCHD, composedof fatal andnonfatalMI andCHD
mortality;andatheroscleroticCVDmortality.14,15PrevalentCVD
was defined as a history of MI, coronary or other arterial re-
vascularization, stroke or focal transient ischemic attack, or
heart failure. Events were assessed until January 1, 2012.
A complete description of themethods formeasurement
of cardiovascular risk factors, definitionsof theoutcomes, and
details regarding the follow-up time is provided in the eAp-
pendix in the Supplement.
Statistical Analyses
We calculated the 10-year risk of hard ASCVD events for each
individual basedon age, systolic bloodpressure, treatment of
hypertension, total and high-density lipoprotein (HDL) cho-
lesterol levels, current smoking, andhistory of diabetesmelli-
tus, using the sex-specific parameters from the ACC/AHA
PooledCohort equations.7Weused the recommended5%and
7.5% risk thresholds for categorization of the 2 respective cat-
egories of “treatment considered” and “treatment
recommended.”5Tocomplywith theACC/AHAguideline,5 the
risk estimation for hard ASCVD was calculated among indi-
vidualswhowerenotreceiving lipid-loweringmedication,were
freeofCVDat baseline, andhad low-density lipoprotein (LDL)
cholesterol levels below 190mg/dL.
Using the continuousATP-III risk predictionmodel based
onage, systolicbloodpressure, treatmentofhypertension, total
andHDLcholesterol levels, andcurrent smoking,16wealsocal-
culated the 10-year risk of hard CHD for the individuals who
werenot receiving lipid-loweringmedication andwere free of
CVD and diabetes mellitus, to comply with the ATP-III
guideline.4 The risk thresholds used for categorization were
10% and 20%, corresponding to the cutoff points for defining
the intermediate- and high-risk categories by the ATP-III
guideline.4
The 10-year risk of CVDmortality for eachparticipantwas
based on age, systolic bloodpressure, total cholesterol levels,
and current smoking using the sex-specific intercepts and re-
gressioncoefficients fromtheSCOREequation for low-riskEu-
ropean countries.17 We used the recommended 1%, 5%, and
10%risk thresholds, corresponding to the cutoff points for de-
fining themoderate-risk, high-risk, andvery-high-riskgroups,
respectively, based on the ESC guideline.6,18 To comply with
the ESC guideline, the SCORE risk estimation was performed
among the individualswhowere not receiving lipid-lowering
medication at baseline and were free of CVD, diabetes melli-
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tus, and chronic kidneydisease (CKD).6Figure 1describes the
inclusion and exclusion criteria for different risk prediction
models.
Based on each guideline, we formed 3 categories of treat-
ment:“treatment recommended,”“treatmentconsidered,”and
“no treatment.” eTables 1 through 3 in the Supplement de-
scribe the criteria used to form these 3 treatment categories
by each guideline.
Weassessed thediscriminationandcalibrationofeach risk
prediction model in our population. Discrimination refers to
ability of themodel to assign a higher risk to individuals who
develop theoutcomeof interest comparedwith thosewho re-
main free of disease. The discriminative performance of each
risk-scoringmodelwas assessed using the C statistic. Calibra-
tion is the agreement between the predicted probabilities of
disease, basedon the risk predictionmodel, and the actual in-
cidence of events in the population. To assess the calibration
of each risk prediction model, the average predicted 10-year
risks for each risk function were compared with the average
10-year observed risks (ie, cumulative incidenceof the event).
Calibration plots were generated to assess the agreement be-
tween the predicted and observed risks over the entire range.
Results
Baseline characteristics of the participants are presented in
Table1.Themeanageof theparticipantswas65.5 (SD,5.2)years
and 54.5% were women.
Basedon theACC/AHAguideline,5 the “treatment recom-
mended” group included 96.4% (95% CI, 95.4%-97.1%;
n = 1825) of men and 65.8% (95% CI, 63.8%-67.7%; n = 1523)
of women while the “treatment considered” group included
3.3% (95% CI, 2.6%-4.2%; n = 63) of men and 14.2% (95% CI,
12.8%-15.7%; n = 330) of women. Only 0.3% of men (95% CI,
0.1%-0.7%;n = 6) and20.0% (95%CI, 18.3%-21.6%;n = 462) of
womenwere categorized in the “no treatment” group (Table 2
and eTable 1 in the Supplement).
Using the ATP-III guideline,4 52.0% (95% CI, 49.8%-
54.3%; n = 985) of men and 35.5% (95% CI, 33.5%-37.5%;
n = 821) of women were categorized in the “treatment rec-
ommended” group, while the “treatment considered” group
included 14.2% (95% CI, 12.6%-15.8%; n = 269) of men and
14.1% (95% CI, 12.7%-15.6%; n = 326) of women. The “no
treatment” category included the remaining 33.8% (95% CI,
Figure 1. Inclusion/Exclusion Criteria for Rotterdam Study Participants for Assessment of Different Guideline Recommendations and Risk Prediction
Models
ACC/AHA Guideline5
3433 Included in risk estimation
for hard ASCVDa
1513 Men
1920 Women
3407 Included in risk estimation
for hard CHDb
1431 Men
1976 Women
3182 Included in risk estimation
for CVD mortality
1366 Men
1816 Women
343 Developed hard ASCVD
during 10-y follow-up
192 Men
86 Stroke
72 Nonfatal MI
26 Fatal CHD
8 Fatal MI
151 Women
92 Stroke
41 Nonfatal MI
15 Fatal CHD
3 Fatal MI
160 Developed hard CHD
during 10-y follow-up
98 Men
65 Nonfatal MI
22 Fatal CHD
11 Fatal MI
62 Women
43 Nonfatal MI
16 Fatal CHD
3 Fatal MI
ATP-III Guideline4 ESC Guideline6
776 Excluded for prevalent
CVD or LDL-C >190
mg/dL (>4.9 mmol/L)
381 Men
395 Women
802 Excluded for prevalent
CVD or DM
463 Men
339 Women
1027 Excluded for prevalent
CVD, DM, or CKD
528 Men
499 Women
645 Excluded for statin use
at baseline
315 Men
330 Women
645 Excluded for statin use
at baseline
315 Men
330 Women
645 Excluded for statin use
at baseline
315 Men
330 Women
87 CVD deaths during 10-y
follow-up
50 Men
37 Women
4854 Total population
2209 Men
2645 Women
4854 Total population
2209 Men
2645 Women
4854 Total population
2209 Men
2645 Women
4209 Included in treatment
recommendations of
ACC/AHA guideline
1894 Men
2315 Women
4209 Included in treatment
recommendations
of ATP-III 
1894 Men
2315 Women
4209 Included in treatment
recommendations of
ESC guideline
1894 Men
2315 Women
ACC/AHA indicates American College of Cardiology/American Heart
Association; ASCVD, atherosclerotic cardiovascular disease; ATP-III, Adult
Treatment Panel III; CHD, coronary heart disease; CKD, chronic kidney disease;
CVD, cardiovascular disease; DM, diabetes mellitus; ESC, European Society of
Cardiology; LDL-C, low-density lipoprotein cholesterol; andMI, myocardial
infarction.
a Hard ASCVD includes fatal CHD, nonfatal CHD, and stroke.
bHardCHD includes fatalmyocardial infarction, nonfatalMI, andCHDmortality.
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31.7%-35.9%; n = 640) of men and 50.4% (95% CI, 48.4%-
52.5%; n = 1168) of women (Table 2 and eTable 2 in the
Supplement).
Based on the ESC guideline,6 66.1% (95% CI, 64.0%-
68.3%; n = 1253) of men and 39.1% (95% CI, 37.1%-41.2%;
n = 906) of women were included in the “treatment recom-
mended” category. The “treatment considered” group com-
prised 31.6% (95%CI, 29.5%-33.7%;n = 598) ofmenand51.4%
(95%CI, 49.3%-53.4%;n = 1189) ofwomen.Only 2.3% (95%CI,
1.6%-2.9%; n = 43) of men and 9.5% (95% CI, 8.3%-10.8%;
n = 220) of women were assigned to the “no treatment” cat-
egory (Table 2 and eTable 3 in the Supplement).
eFigure 1 in the Supplement presents the treatment rec-
ommendations based on the 3 guidelines for the populations
younger than65years andaged65yearsorolder. Thedata sug-
gest that almost all men older than 55 years and nearly all
womenolder than 65 years are recommended for statin treat-
ment based on the new ACC/AHA guideline.
eTables 1 through 3 in the Supplement show thatwhile all
men andwomenwith prevalent CVDwere categorized in the
“treatment recommended” group by the ACC/AHA guideline
(eTable 1 in theSupplement), 12.9%ofmenand4.2%ofwomen
with clinical CHD and CHD risk equivalents were categorized
in the “treatment considered” or “no treatment” category
based on the ATP-III guideline (eTable 2 in the Supplement).
Using theESCguideline, a small groupof individualswithclini-
calCVDand its riskequivalents (0.6%ofmenand0.4%ofwom-
en) were categorized in the “treatment considered” group
(eTable 3 in the Supplement).
eTables 4 through 6 in the Supplement provide the de-
scriptionof theproportionof thepopulation towhomeachrisk
estimation model was applied. Among 1513 men and 1920
women included for ASCVD risk prediction (ACC/AHA), 192
men and 151 women developed hard ASCVD over 10-year fol-
low-up. Among 1431 men and 1976 women included for CHD
risk prediction (ATP-III), hardCHDoccurred in 98menand62
women over 10-year follow-up. Among 1366 men and 1816
women included for CVD mortality risk prediction (ESC), 50
men and 37 women died of atherosclerotic CVD over 10-year
follow-up. For all outcomes studied, follow-up timewas trun-
cated at 10 years for individuals with a longer follow-up time
than 10 years.
After calculating the 10-year risk for individuals based on
each risk prediction model, we first assessed the discrimina-
tive ability of each model. The C statistic for the ACC/AHA
model was 0.67 (95% CI, 0.63-0.71) for men and 0.68 (95% CI,
0.64-0.73) for women for hard ASCVD. Use of the ATP-III risk
predictionmodel resulted in aC statistic of 0.67 (95%CI, 0.62-
0.72) formen and 0.69 (95%CI, 0.63-0.75) forwomen for hard
CHD.Using the SCOREequation (ESC), theC statisticwas0.76
(95% CI, 0.70-0.82) for men and 0.77 (95% CI, 0.71-0.83) for
women for CVDmortality.
We then assessed the calibration of each risk prediction
model. Figure 2 compares the average 10-year risks predicted
by theACC/AHA,ATP-III, or SCORE (ESC) riskpredictionmod-
els with the observed 10-year risks (ie, cumulative incidence
of events) in each risk category. Calibration was poor for all 3
models; theACC/AHA (Figure 2A), theATP-III (Figure 2B), and
theSCOREequation (Figure 2C)overestimated the 10-year risk
amongmen andwomen across all risk categories. eTable 7 in
the Supplement details the percentage of population at dif-
ferent categories of risk using each risk predictionmodel. The
average predicted risks vs observed cumulative incidence of
Table 1. Characteristics of the Study Population at Baseline
Characteristics
Men
(n = 2209)
Women
(n = 2645)
Age, mean (SD), y 65.5 (5.3) 65.4 (5.2)
Blood pressure, mean (SD), mm Hg
Systolic 143 (21) 140 (21)
Diastolic 79 (11) 76 (11)
Antihypertensive treatment, No. (%) 468 (21.2) 643 (24.3)
Body mass index, mean (SD)a 26.7 (3.3) 27.3 (4.5)
Total cholesterol, mean (SD), mg/dL
[mmol/L]
216.2 (37.1)
[5.60 (0.96)]
232.7 (35.7)
[6.03 (0.92)]
HDL cholesterol, mean (SD), mg/dL
[mmol/L]
47.7 (12.1)
[1.24 (0.31)]
58.1 (14.9)
[1.50 (0.39)]
LDL cholesterol, mean (SD), mg/dL
[mmol/L]
140.2 (34.4)
[3.63 (0.89)]
147.9 (34.4)
[3.83 (0.89)]
Statin treatment at baseline, No. (%)b 315 (14.3) 330 (12.5)
Current smoking, No. (%) 437 (19.8) 522 (19.7)
Diabetes mellitus, No. (%) 315 (14.3) 282 (10.7)
Chronic kidney disease, No. (%) 139 (6.3) 226 (8.5)
Prevalent CVD, No. (%) 414 (18.7) 186 (7.0)
Abbreviations: CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
a Calculated as weight in kilograms divided by height in meters squared
bNo. (%) of men and women receiving lipid-lowering medication at baseline.
(Statins constituted 96% of all lipid-lowering medications at baseline).
Table 2. Treatment Recommendations Based on Different Guidelines
Treatment Categories
Guidelinea
ACC/AHA5 ATP-III4 ESC6
Men (n = 1894)b
Treatment recommended 96.4 (95.4-97.1) 52.0 (49.8-54.3) 66.1 (64.0-68.3)
Treatment considered 3.3 (2.6-4.2) 14.2 (12.6-15.8) 31.6 (29.5-33.7)
No treatment 0.3 (0.1-0.7) 33.8 (31.7-35.9) 2.3 (1.6-2.9)
Women (n = 2315)b
Treatment recommended 65.8 (63.8-67.7) 35.5 (33.5-37.5) 39.1 (37.1-41.2)
Treatment considered 14.2 (12.8-15.7) 14.1 (12.7-15.6) 51.4 (49.3-53.4)
No treatment 20.0 (18.3-21.6) 50.4 (48.4-52.5) 9.5 (8.3-10.8)
Abbreviations: ACC/AHA, American
College of Cardiology/American Heart
Association; ATP-III, Adult Treatment
Panel III; ESC, European Society of
Cardiology.
a Data are percentage of the
population (95% CI) in different
categories of treatment
recommendations based on the
2013 ACC/AHA,5 2001 ATP-III,4 and
2012 ESC guidelines.6
b Individuals receiving statin
treatment at baseline (n = 315 men
and n = 330women) were
excluded.
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Figure 2. Observed vs Predicted Risks by the ACC/AHA RiskModel, ATP-III RiskModel, and SCORE Equation Among Rotterdam Study Participants
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A, Comparison of average observed hard atherosclerotic cardiovascular disease
(ASCVD) risk over 10-year follow-up (ie, cumulative incidence of hard ASCVD) vs
average predicted 10-year hard ASCVD risk by the American College of
Cardiology/American Heart Association (ACC/AHA) risk predictionmodel7
across categories of risk for men (n = 1513) and women (n = 1920). Individuals
receiving statin treatment at baseline, with prevalent CVD, or with low-density
lipoprotein cholesterol levels >190mg/dL were excluded. B, Comparison of
average observed hard coronary heart disease (CHD) risk over 10-year follow-up
(ie, cumulative incidence of hard CHD) vs average predicted 10-year hard CHD
risk by the Adult Treatment Panel III (ATP-III) risk predictionmodel16 across
categories of risk for men (n = 1431) and women (n = 1976). Individuals
receiving statin treatment at baseline and those with prevalent CVD or diabetes
mellitus were excluded. C, Comparison of average observed CVDmortality risk
over 10-year follow-up (ie, cumulative incidence of CVDmortality) vs average
predicted 10-year CVDmortality risk by the SCORE equation17 across categories
of risk for men (n = 1366) and women (n = 1816). Individuals receiving statin
treatment at baseline and those with prevalent CVD, diabetes mellitus, or
chronic kidney disease were excluded.
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hardASCVDeventswere 21.5% (95%CI, 20.9%-22.1%)vs 12.7%
(95% CI, 11.1%-14.5%) for men and 11.6% (95% CI, 11.2%-
12.0%) vs 7.9% (95%CI, 6.7%-9.2%) forwomenusing theACC/
AHA risk model. The average predicted vs observed cumula-
tive incidencesofhardCHDeventswere 16.1% (95%CI, 15.8%-
16.5%) vs 6.8% (95%CI, 5.6%-8.3%) formenand5.4% (95%CI,
5.2%-5.5%) vs 3.1% (95% CI, 2.4%-4.0%) for women based on
theATP-III. Using the SCORE equation, the average predicted
vsobservedcumulative incidencesofCVDmortalitywere6.8%
(95% CI, 6.5%-7.1%) vs 3.7% (95% CI, 2.7%-4.8%) formen and
3.8% (95% CI, 3.7%-4.0%) vs 2.0% (95% CI, 1.4%-2.8%) for
women. Calibration plots for the ACC/AHA, the ATP-III, and
the ESC risk prediction models are presented in eFigures 2
through 4 in the Supplement.
Discussion
In this European population-based prospective cohort study
of healthy men and women without previous CVD (ie, pri-
marypreventionpopulation) aged 55 years or older,we found
that nearly all men and more than 65% of women were rec-
ommended for drug treatment based on the recent ACC/AHA
guideline.5
Regarding secondary prevention of CVD, the ACC/AHA
guidelines clearly recommend drug treatment for all persons
with clinical CVD and its risk equivalents.5 Based on the ATP-
III and ESC guidelines, however, it is possible that some indi-
vidualswithclinicalCVDarecategorized into2groupsof“treat-
ment considered” or “no treatment” based on their LDL
cholesterol levels.4,6
For primary CVDprevention, based on the evidence from
clinical trials of statin drugs,19 the new ACC/AHA guidelines
modified clinical decision making and proposed to recom-
mend statin treatment solely based on a 10-year ASCVD risk
greater than 7.5%.5 This departure from previous guidelines
in the United States and from the current ESC guideline rep-
resents a fairly straightforward approach that deviates from
risk functions of 10-year hard CHD or CVD mortality com-
bined with blood concentrations of LDL cholesterol.4,6
The new ACA/AHA guideline recommendations resulted
ina larger“treatment recommended”group inourpopulation5
in contrast to the larger “treatment considered” group based
on the ESC guidelines.6 This raises questions about the use of
a risk assessment calculator for treatment decisions when so
large aproportionof the older population is among the “treat-
ment recommended”group.Adecadeago,WaldandLaw20de-
scribeda radical strategy topreventCVDbyprescribing adaily
polypill to everyone aged 55 years or older without requiring
risk factors to bemeasured. Our results suggest that by inclu-
sion of stroke as an outcome and applying the lowered evi-
dence-based risk threshold of 7.5% for treatment,19,21 thenew
ACC/AHAguidelines have approached this “age-based” strat-
egy. In our population, almost allmenolder than 55 years and
almost allwomenolder than65years qualified for statin treat-
ment based on the ACC/AHA guidelines.5
The clinical usefulness of a risk prediction tool is deter-
mined by a combination of its discrimination and calibration.
In our study, the C statistic for the 3 risk prediction models
rangedbetween0.67and0.77, indicatingmoderate togooddis-
crimination, with the SCORE equation providing the highest
C statistic among the 3 models. Theoretically, if a model has
perfectdiscrimination (ie, theCstatistic exceeds0.98), thecut-
off threshold for treatment can be set at any level. However,
themodest discrimination ability of the risk predictionmod-
els in our study indicates that there is a substantial overlap in
the risk distributions of the individuals with andwithout the
events. Therefore, given the current performance of theACC/
AHA risk prediction model, the place of the cutoff threshold
for treatment is essential.
When an individual’s absolute risk prediction is used for
clinical decision making regarding initiation of treatment,
accurate calibration is very important. As also evident from
our analyses, concerns regarding model calibration are perti-
nent to all 3 of the risk prediction models; to the Framing-
ham risk score that formed the basis for the ATP-III,22-24 to
the SCORE equation,25 and recently to the new ACC/AHA risk
calculator.12 Miscalibration of the risk prediction models,
once applied in other populations rather than derivation
sets, is expected.26 Imperfect calibration could partly be
explained by differences in the characteristics of the new
populations, ie, different levels of baseline risk, for which
the risk prediction model is applied. Furthermore, if the
application cohorts are more contemporary to the cohorts
used in the derivation sets, temporal improvements in over-
all health could partly be responsible for poor calibration.
The risk prediction models underlying all 3 guidelines over-
estimated the risk among men and women in our study.
About 17% of men and 16% of women included in the ASCVD
risk assessment in our study were eventually prescribed stat-
ins over the course of follow-up. Based on the premise that
healthy lifestyle and therapeutic measures would reduce the
CVD burden, statin prescription together with improvement
of high blood pressure treatment, aspirin use, higher smok-
ing quit rates, and other lifestyle modifications over the
follow-up period might have contributed to the observed
overestimations to some extent.
Related closely to the calibration issue is the threshold for
making clinical decisions. The newACC/AHA guidelines sub-
stantially lowered the cutoff for treatment to an evidence-
based threshold of 7.5%.19,21 If the new ACC/AHA risk predic-
tion model led to overestimation among individuals at high
levels of actual CVD risk (eg, >20% estimated 10-year risk), it
wouldnotnecessarily affect theeventual proportionofpeople
recommendedforconsiderationof statinuse.However, among
individualswith lower actualCVDrisks, overestimationby the
risk prediction models is of much greater concern. Inaccu-
racy of the predictionmodels at the lower levels of risk could
indeed result inmanymore individuals recommended for stat-
ins thanwere intended.While not explicitly stated in thenew
ACC/AHA guideline, setting of thresholds typically involves
both an awareness of clinical benefit of the treatment in the
target population combined with a judgment about cost-
effectiveness. Different countries and settingsmay decide on
very different thresholds based on cost-effectiveness or re-
source considerations, which is another reason to look criti-
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cally at the clinical implicationsof the risk estimation tool and
the risk threshold in other non-US settings. Beyond the need
for improving the risk predictions and setting appropriate
population-wide thresholds to facilitate better clinical deci-
sion making, the large proportion of the population recom-
mended for statin treatment based on new guidelines should
beaconcerningsignal.These largenumberspointout theneed
for (1) preventing risk factor aggregation and (2) conveying in-
formation to individuals in ways that effectively lower their
risk, in an era when cardiovascular disease remains a world-
wide public health challenge.
Strengthsof thecurrent study includeavailabilityofall risk
factorsneeded fordifferent riskpredictionmodels,whichwere
measured with standardized methods, and detailed fol-
low-up data. However, an important limitation is that our co-
hort includeswhite individuals aged 55 years or older. There-
fore, the generalizability of our findings to younger and
nonwhite populations remains uncertain. Furthermore, this
study had relatively small numbers of events for some out-
comes.
Conclusions
Withapplicationof the recentACC/AHAguidelines inahealthy
Europeanpopulation-basedcohort,nearlyallmenandthema-
jorityofwomenaged55yearsorolderwerecandidates fordrug
treatment. Application of the ACC/AHA, ATP-III, and ESC risk
predictionmodels led to overestimation of the risk. Given the
modest discrimination and poor calibration of the ACC/AHA
risk prediction model, the choice of treatment threshold be-
comes central.
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